Диссертация (1140655), страница 26
Текст из файла (страница 26)
The role of urinary urgencyand its measurement in the overactive bladder syndrome: Current conceptsand future prospects // Br J Urol Int. – 2005. – Vol. 95. – P. 335-340.60.Abrams P., Artibani W., Cardozo L. et al. Reviewing the ICS 2002terminology report: The ongoing debate // Neurourol Urodyn. – 2006. – Vol.25. – P. 293.61.European Agency for the Evaluation of Medical Products. Committee for thetreatment of urinary incontinence in women / - London, November 2002.62.Cardozo L., Coyene K., Versi E. Validation of the urgency perception scale //Br J Urol Int. – 2005. – Vol.
95. – P. 591-596.63.Abrams P., Cardozo L., Fall M. et al. The overactive bladder: from basicscience to clinical mabagement // Urology(suppl. 6A). – 1997. – Vol. 50. –P. 1-144.64.Blavias J.C., Panagopoulos G., Weis J.P. et al. The urgency perceprion score:The urgency perception score: Validation and test-retest // J. Urol.(Baltimore). – 2007.
– Vol. 77. – P. 192-202.65.De Wachter S., Wyndaele J.J. How sudden is a compelling desire to void?An observational cystometric study on the suddenness of this sensation //BJU Int. – 2008 Apr. – Vol. 101(8). – P. 1000-3.66.Coyne K., Matza L. S., Versi E. Urinary urgency: Can ''gorra go'' bemeasured? Jn: The 10th Annual meeting of the International Society forQuality of Life Research / – Prague, 2003.17067.Lukacz E.S., Lawrence J.M., Burchette R.J. et al. The use of Visual AnalogScale in urogynecologic research: A psychometric evaluation // Am.
J.Obstert Gynecol. – 2004. – Vol. 191. – P. 165-170.68.Freeman R.M. How urgent is urgency? A rewiev of current methods ofassessment // Int. Urogynecol. J. Pelvic Floor Dysfunct. – 2005. – Vol.16. –P. 93-95.69.Zinner N., Harnett M., Sabounjian L. et al.
The overactive bladder-symptomcomposite score: A composite symptom score of toilet voids, urgency andurge urinary incontinence in patients with overactive bladder // J. Urol.(Baltimore). – 2005. – Vol. 173. – P. 1639-1643.70.Yamaguchi O., Honda K., Nomiya M. Defining overactive bladder ashypersensitivity //Neurourol. and Urodyn.
(Baltimore)(suppl. 6). – 2007. –Vol. 26. – P. 904-907.71.Jeffcoate Т.N.A., Francis W.J.A. Urgency incontinence in the female. // AmJ Obstet Gynecol. – 1966. – Vol. 94. – P. 604 – 618.72.Fantl J.A., Wyman J.F., McClish D.K.et al. Efficacy of bladder training inolder women with urinary incontinence. // Journal of the American MedicalAssociation. –1991. – Vol. 265(5). – P. 609 – 61.73.O`Donnel P.D.
Biofeedback Therapy / In: Female Urology, ed. Shlomo Raz.nd– 2 ed. W.B. Saunders company, Philadelphia – London – Toronto –Montreal – Sydney – Tokyo. – 1996. – P. 253 – 261.74.Kegel A.H. Physiologic treatment of poor tone and function of the genitalmuscles and urinary stress incontinence // West J Surg. – 1949. – Vol. 57. –P. 527 – 535.75.Kegel A.H. Progressive resistance exercise in the functional restoration ofthe perineal muscles. // Am J Obstet Gynecol. – 1948. – Vol. 56 (2). – P.238-248.76.Wyndaele J.J., Hoekx L., Vermandel A. Bladder biofeedback for thetreatment of refractory sensory urgency in adults // Eur. Urol.
– 1997. – Vol.32 (4). – P. 429-32.17177.Burgio K.L., Locher J.L., Goodie P.S. et al. Behavioral vs. drug treatment forurge urinary incontinence in older women: a randomized controlled trial //JAMA. –1998, Dec 16. – Vol. 280 (23). – P. 1995-2000.78.Аполихина И. А., Андикян В.М., Ромих В.В.
Тренировка мышцтазового дна в режиме биологической обратной связи в лечениинедержания мочи у женщин // Материалы VI Всероссийского форума«Мать и дитя». – М., 2004. – С. 281 – 282.79.Абоян В.Э., Абоян И.А., Павлов С.В. и др. Применение биологическойобратной связи в лечении больных ургентным недержанием мочи //Пленум Всероссийского общества урологов : Тез. докл.
– Тюмень, 2005.– С. 352 – 353.80.Hay-Smith E.J., B K., Berghmans L.C. et al. Withdrawn: Pelvic floormuscle training for urinary incontinence in women / Cochrane Database Syst.Rev. – 2007, Jul.18. – (1): CD001407.81.Лоран О.Б.,ПушкарьД.Ю.,ТевлинК.П.Применение дриптана (оксибутинина) у больных с императивнымиформами расстройств мочеиспускания // Урология 1998. – № 4 — С.2426.82.ЛопаткинН.А.,ПерепановаТ.С.,АлленовС.Н.,АляевЮ.Г.Рациональная фармакотерапия в урологии - М. Литтерра, 2006 – 804 с.83.Nitti V.W., Dmochowski R., Sand P.K., et al.: Efficacy, safety andtolerability of fesoterodine for overactive bladder syndrome // J Urol.
–2007. – Vol. 178. – P. 2488-94.84.Michel M.C. Fesoterodine: a novel muscarinic receptor antagonist for thetreatment of overactive bladder syndrome // Expert Opin Pharmacother. –2008. – Vol. 9. – P. 1787-96.85.Michel M.C., Hegde S.S. Treatment of the overactive bladder syndrome withmuscarinic receptors antagonists – a matter of metabolites? // NaunynSchmiedeberg Arch Pharmacol. – 2006.
– Vol. 274. – P. 79-85.17286.Herschorn S., Swift S., Guan Z. et al. Comparison of fesoterodine andtolterodine extended release for the treatment of overactive bladder: a headto-head placebo-controlled trial //BJU Int. – 2010 Jan. – Vol. 105(1). – P. 5866.87.Nitti V.W., Rovner E.S., Bavendam T. Response of fesoterodine in patientswith an overactive bladder and urgency urinary incontinence is independentof the urodynamic finding of detrusor overactivity // Journal Compilation. –2009 – Vol.
105. – P. 1268-1275.88.Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism ofaction // Neurol Urodyn. – 2010. – Vol. 29 (1). – P. 112-5.89.Kim Y., Yoshimura N., Masuda H et al. Antimuscarinic agents exhibit localinhibitory effects on muscarinic receptors in bladder-afferent pathways //Urology. – 2005 Feb. – Vol. 65 (2). – P. 238-42.90.Харкевич Д. А. Фармакология: учебник. – 10-е изд., испр., перераб.
идоп. – М.: ГЭОТАР-Мед, 2010. - 752 с.91.Nergardh A., Boréus L.O., Naglo A.S. Characterization of the adrenergicBeta-receptor in the urinary bladder of man and cat // Acta PharmacolToxicol. – 1977. – Vol. 40. – P. 14-21.92.Takeda M., Obara K., Mizusawa T. et al.
Evidence for beta 3-adrenoceptorsubtypes in relaxation of the human urinary bladder detrusor: Analysis bymolecular biological and pharmacological methods // J Pharmacol Exp Ther.– 1999. – Vol.288. – P. 1367-1373.93.Yamazaki Y., Takeda H., Akahane M.et al. Species differences in thedistribution of beta-adrenoceptor subtypes in bladder smooth muscle // Br JPharmacol. – 1998. – Vol. 124.
– P. 593-599.94.Levin R.M., Ruggieri M.R., Wein A.J. Identification of receptor subtypes inthe rabbit and human urinary bladder by selective radio-ligand binding // JUrol. – 1988. – Vol. 139. – P. 844-848.17395.Fujimura T., Tamura K., Tsutsumi T. et al. Expression and possiblefunctional role of beta 3-adrenoceptors in human and rat detrusor muscle // JUrol. – 1999. – Vol. 161.
– P. 680-685.96.Takeda H., Yamazaki Y., Akahane M. et al. Role of the beta 3-adrenoceptorin urine storage in the rat: comparison between the selective beta 3adrenoceptor agonist, CL316423, and various smooth muscle relaxants // JPharmacol Exp Ther. – 2000. – Vol. 293. – P. 939-945.97.Kaidoh K., Igawa Y., Takeda H. et al. Effects of selective beta2 and beta 3adrenoceptor agonists on detrusor hyperreflexia in conscious cerebralinfarcted rats // J Urol. – 2002.
– Vol. 168. – P. 1247-1252.98.Woods M., Carson N., Norton N.W.et al. Efficacy of the beta 3-adrenergicreceptor agonist CL-316243 on experimental bladder hyperreflexia anddetrusor instability in the rat // J Urol. – 2001. – Vol. 166. – P. 1142-1147.99.Yamaguchi O. Beta 3-adrenoceptors in human detrusor muscle //Urology(Suppl 1). – 2002.
– Vol. 59. – P. 25-29.100.Kumar V., Templeman L., Chapple C.R., Chess-Williams R. Recentdevelopments in the management of detrusor overactivity // Curr Opin Urol.– 2003. – Vol. 13. – P. 285-291.101.Tyagi P., Tyagi V., Chancellor M. Mirabegron: a safety review //Expert Opin Drug Saf. – 2011, Mar. – Vol. 10 (2).
– P. 287-94.102.Chapple C., Wyndaele J.J., Van Kerrebroeck P., et al. Dose-RangingStudy Of Once-Daily Mirabegron (Ym178), A novel selective beta3adrenoceptor agonist, in patients with overactive bladder (OAB). EuropeanUrology Association Annual conference/ - Barcelona, 2010. – Elsevier BV. –P. 249.103.Khullar V., Amarenco G., Angulo J.C. et al. Efficacy and tolerabilityof mirabegron, a beta3-adrenoceptor agonist, in patients with overactivebladder: Results from a randomised European-Australian phase 3 trial // EurUrol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
